Le Lézard
Classified in: Business
Subjects: BOARD OF DIRECTORS, MISCELLANEOUS, MISCELLANEOUS

MaRS Innovation appoints Steven Chackowicz as Executive-in-Residence


Toronto, ON, June 25, 2018 (GLOBE NEWSWIRE) -- MaRS innovation (MI) announced today that Steven Chackowicz has been appointed Executive-in-Residence where he will oversee the technology scouting and commercialization efforts for MI in the medical device space.

Steven Checkowicz is an experienced technology executive. A serial entrepreneur in early-stage companies, he defined and executed strategies and tactics that enabled newly formed companies to move to significant commercial success.  Steven has been successful in assisting companies toward positive liquidity events by driving revenue growth and new product adoption in the healthcare and life sciences sectors. Prior to joining MI, Steven was the CEO of Nanovista, a company focused on imaging agents for precision medicine and worked with the lead investors to successfully close the financing. He has previously held executive positions at Exact Imaging, Aspect Imaging and VisualSonics. Steven earned his Bachelor of Science, Honours in biochemistry with a minor in metaphysics and epistemology at the University of Toronto.

"We are extremely pleased to be able to recruit an executive with such intimate knowledge and expertise in the medical device arena" said Rafi Hofstein, President and CEO of MI. "MI's Members offer a rich pipeline of technologies in that space, and Steven joining MI means we have the seasoned oversight to develop the best and most promising of these new inventions in a professional and expedient manner. Through this new hire, MI continues to add to its roster of talented staff and executives."

About MaRS Innovation

MaRS Innovation is a leading provider of commercialization services, early-stage funding, and deal-brokering with industry and private investors. As a member-based organization made up of 15 member institutions, our mandate is to drive the commercialization of their most promising research breakthroughs. MaRS Innovation's portfolio consists of early-stage assets and companies, and we leverage our deep expertise and experience to mature this portfolio via important global and strategic partnerships. With an active portfolio of more than 40 companies which have raised in excess of $250M from global investors, and with the creation of more than 400 direct jobs, MaRS Innovation is truly a leader in the commercialization field. For more information please visit www.marsinnovation.com and follow us on Twitter @marsinnovation.


These press releases may also interest you

at 01:49
Aker BP delivered continued strong operational performance in the first quarter of 2024, with low cost and low emissions, and with all field development projects progressing according to plan.  HighlightsIncreased production: Oil and gas production...

at 01:41
Solus Power, a leading innovator in electric vehicle (EV) charging solutions, has signed a Memorandum of Understanding (MOU) with global defence and security company, QinetiQ....

at 01:25
Well positioned for the gardening season First quarter 2024            Net sales decreased by 14% to SEK 14,719m (17,167). Changes in exchange rates had a neutral effect. Planned exits of low-margin petrol-powered business impacted with -4%. Organic...

at 01:24
Volvo Cars today reports an operating profit (EBIT) excluding joint ventures...

at 01:05
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1...

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...



News published on and distributed by: